Javascript must be enabled to continue!
Supplementary Figures S1-S25 from Late-stage metastatic melanoma emerges through a diversity of evolutionary pathways
View through CrossRef
<p>Supplementary figure 1: Cohort overview. Number of samples sequenced with whole exome, panel or whole
RNA sequencing.
Supplementary figure 2: Phylogeny and WGD events in CRUKP1047.
Supplementary figure 3: Ploidy and SCNA burden.
Supplementary figure 4: Overview of each case.
Supplementary figure 5: MEDICC2 copy number sample trees.
Supplementary figure 6: MEDICC tree of all exome samples demonstrating that samples cluster together by patient, and not by melanoma subtype.
Supplementary figure 7: SCNA frequency of cutaneous (a), acral (b) and melanoma of unknown primary (MUP, c).
Supplementary figure 8: Correlation between liver copy number distance to other sites and time of emergence after stage IV diagnosis.
Supplementary figure 9: Examination of tumour heterogeneity of alterations to antigen-presentation machinery genes,with site and patient annotation.
Supplementary figure 10: Boxplots indicating the proportion of losses in the cohort for each segment.
Supplementary figure 11: Balance of expression between nonsynonymous mutations that were not predicted to be neoantigens and clonal predicted neoantigens.
Supplementary figure 12: Barplot of TIL infiltration score frequencies, determined by pathologist assessment of histology, across all samples.
Supplementary figure 13: Number of samples per patient that are classified as either none-low in terms of TILs or moderate-heavy.
Supplementary figure 14: Histogram of purity for samples with RNA-seq data.
Supplementary figure 15: TME deconvolution.
Supplementary figure 16: The effect of metastatic site on transcriptional profiles.
Supplementary figure 17: Association of PHF3 copy number with expression.
Supplementary figure 18: Overview of gene fusions identified in RNA-seq data.
Supplementary figure 19: Comparison of ploidy estimates from panel sequencing data, exome data and FISH.
Supplementary figure 20: Comparison of ploidy estimates in panel, exome, FISH and single cell data.
Supplementary figure 21: FACs sort plot for CRUKP2567 diaphragmatic metastasis.
Supplementary figure 22: Ploidy and wGII values from single cell sequencing of FACS-sorted tumour cells.
Supplementary figure 23: Copy number profiles on chromosome 5 for bulk samples from primary and DI_2_R2, a diaphragmatic metastasis.
Supplementary figure 24: Histogram of purity of samples for which RNA-seq was performed faceted by patient.
Supplementary figure 25: Histogram of purity of samples for which RNA-seq was performed faceted by tissue site.</p>
American Association for Cancer Research (AACR)
Lavinia Spain
Alexander Coulton
Irene Lobon
Andrew Rowan
Desiree Schnidrig
Scott T.C. Shepherd
Benjamin Shum
Fiona Byrne
Maria Goicoechea
Elisa Piperni
Lewis Au
Kim Edmonds
Eleanor Carlyle
Nikki Hunter
Alexandra Renn
Christina Messiou
Peta Hughes
Jaime Nobbs
Floris Foijer
Hilda van den Bos
Rene Wardenaar
Diana C.J. Spierings
Charlotte Spencer
Andreas M. Schmitt
Zayd Tippu
Karla Lingard
Lauren Grostate
Kema Peat
Kayleigh Kelly
Sarah Sarker
Sarah Vaughan
Mary Mangwende
Lauren Terry
Denise Kelly
Jennifer Biano
Aida Murra
Justine Korteweg
Charlotte Lewis
Molly OFlaherty
Anne-Laure Cattin
Max Emmerich
Camille L. Gerard
Husayn Ahmed. Pallikonda
Joanna Lynch
Robert Mason
Aljosja Rogiers
Hang Xu
Ariana Huebner
Nicholas McGranahan
Maise Al Bakir
Jun Murai
Cristina Naceur-Lombardelli
Elaine Borg
Miriam Mitchison
David A. Moore
Mary Falzon
Ian Proctor
Gordon W H. Stamp
Emma L. Nye
Kate Young
Andrew J.S. Furness
Lisa Pickering
Ruby Stewart
Ula Mahadeva
Anna Green
James Larkin
Kevin Litchfield
Charles Swanton
Mariam Jamal-Hanjani
Samra Turajlic
Title: Supplementary Figures S1-S25 from Late-stage metastatic melanoma emerges through a diversity of evolutionary pathways
Description:
<p>Supplementary figure 1: Cohort overview.
Number of samples sequenced with whole exome, panel or whole
RNA sequencing.
Supplementary figure 2: Phylogeny and WGD events in CRUKP1047.
Supplementary figure 3: Ploidy and SCNA burden.
Supplementary figure 4: Overview of each case.
Supplementary figure 5: MEDICC2 copy number sample trees.
Supplementary figure 6: MEDICC tree of all exome samples demonstrating that samples cluster together by patient, and not by melanoma subtype.
Supplementary figure 7: SCNA frequency of cutaneous (a), acral (b) and melanoma of unknown primary (MUP, c).
Supplementary figure 8: Correlation between liver copy number distance to other sites and time of emergence after stage IV diagnosis.
Supplementary figure 9: Examination of tumour heterogeneity of alterations to antigen-presentation machinery genes,with site and patient annotation.
Supplementary figure 10: Boxplots indicating the proportion of losses in the cohort for each segment.
Supplementary figure 11: Balance of expression between nonsynonymous mutations that were not predicted to be neoantigens and clonal predicted neoantigens.
Supplementary figure 12: Barplot of TIL infiltration score frequencies, determined by pathologist assessment of histology, across all samples.
Supplementary figure 13: Number of samples per patient that are classified as either none-low in terms of TILs or moderate-heavy.
Supplementary figure 14: Histogram of purity for samples with RNA-seq data.
Supplementary figure 15: TME deconvolution.
Supplementary figure 16: The effect of metastatic site on transcriptional profiles.
Supplementary figure 17: Association of PHF3 copy number with expression.
Supplementary figure 18: Overview of gene fusions identified in RNA-seq data.
Supplementary figure 19: Comparison of ploidy estimates from panel sequencing data, exome data and FISH.
Supplementary figure 20: Comparison of ploidy estimates in panel, exome, FISH and single cell data.
Supplementary figure 21: FACs sort plot for CRUKP2567 diaphragmatic metastasis.
Supplementary figure 22: Ploidy and wGII values from single cell sequencing of FACS-sorted tumour cells.
Supplementary figure 23: Copy number profiles on chromosome 5 for bulk samples from primary and DI_2_R2, a diaphragmatic metastasis.
Supplementary figure 24: Histogram of purity of samples for which RNA-seq was performed faceted by patient.
Supplementary figure 25: Histogram of purity of samples for which RNA-seq was performed faceted by tissue site.
</p>.
Related Results
Supplementary Figures S1-S25 from Late-stage metastatic melanoma emerges through a diversity of evolutionary pathways
Supplementary Figures S1-S25 from Late-stage metastatic melanoma emerges through a diversity of evolutionary pathways
<p>Supplementary figure 1: Cohort overview. Number of samples sequenced with whole exome, panel or whole
RNA sequencing.
Supplementary figure 2: Phylogeny and WGD events in ...
Abstract LB163: Germline pathogenic variants in melanoma patients
Abstract LB163: Germline pathogenic variants in melanoma patients
Abstract
Background: The etiology of melanoma has generally been thought to be exposure to UV radiation (sun and sun tanning lamps). However, the percent of melanoma...
Divergent pathways of melanoma development: evidence from a Southern European cohort
Divergent pathways of melanoma development: evidence from a Southern European cohort
Nevus counts in the divergent pathway model of melanoma development have been studied mainly in patients in Australia. Our aim was to compare nevus counts and the melanoma subtype ...
Abstract 3387: Mutational analysis in metastatic melanoma to the breast and ovary: correlation with clinic-pathological and immunohistochemical findings
Abstract 3387: Mutational analysis in metastatic melanoma to the breast and ovary: correlation with clinic-pathological and immunohistochemical findings
Abstract
Metastatic malignant melanoma or stage IV melanoma is the most deadly skin cancer, claiming an estimated 10,000 deaths every year. The occurrence of metasta...
Abstract 336: IL-6 primes melanoma cells from early stages to statin induced apoptosis
Abstract 336: IL-6 primes melanoma cells from early stages to statin induced apoptosis
Abstract
Introduction: Statins trigger apoptosis in tumour cells in vitro and, particularly, melanoma cells are susceptible to statin induced apoptosis.
...
YAP1 and downstream gene alterations in metastatic breast cancer.
YAP1 and downstream gene alterations in metastatic breast cancer.
e13121
Background:
Metastatic breast cancer remains a major clinical challenge, characterized by poor prognosis and limited therapeuti...
Modeling melanoma in reconstructed human skin
Modeling melanoma in reconstructed human skin
With increasing pressure from the European Union to replace, reduce, and refine animal experiments, there is a critical need for models that reliably mimic human diseases in a phys...
Construction of competing endogenous RNA interaction networks as prognostic markers in metastatic melanoma
Construction of competing endogenous RNA interaction networks as prognostic markers in metastatic melanoma
Abstract
Malignant melanoma (MM) is a highly aggressive, metastatic cancer originating from melanocytes. These tumors have an extremely poor prognosis. MM accounts ...

